USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Fan, Y H ^a   Cheng, J ^a   Vasudevan, S A ^b   Dou, J ^c,d   Zhang, H ^c,c   Patel, R H ^b   Ma, I T ^b   Rojas, Y ^b   Zhao, Y ^a   Yu, Y ^c   Shohet, J M ^a   Nuchtern, J G ^b   Kim, E S ^b   Yang, J ^a  

^a TEXAS CHILDREN S CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY   (China)

Author keywords

Chemotherapy; Neuroblastoma; P22077; P53; USP7 inhibitor

Indexed keywords

1 [5 [(2,4 DIFLUOROPHENYL)THIO] 4-NITROTHIOPHEN 2 YL]ETHANONE; DOXORUBICIN; ETOPOSIDE; P 22077; PROTEIN MDM2; PROTEIN P53; PROTEINASE; PROTEINASE INHIBITOR; UBIQUITIN SPECIFIC PROTEASE 7; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPES SIMPLEX VIRUS PROTEIN VMW65; HUMANS; MICE; NEUROBLASTOMA; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; THIOPHENES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN THIOLESTERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887471999     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.400     Document Type: Article

References (37)

1. Alderton GK, Bordon Y. Tumour immunotherapy-leukocytes take up the fight. Nat Rev Immunol 2012; 12: 237
2. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: Challenges and future directions. Nat Rev Cancer 2011; 11: 59-67
3. Vander Heiden MG. Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov 2011; 10: 671-684
4. Tu Z, Hao J, Kharidia R, Meng XG, Liang JF. Improved stability and selectivity of lytic peptides through self-assembly. Biochem Biophys Res Commun 2007; 361: 712-717
5. Papo N, Shai Y. New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 2003; 42: 9346-9354
6. Zhong J, Chau Y. Antitumor activity of a membrane lytic peptide cyclized with a linker sensitive to membrane type 1-matrix metalloproteinase. Mol Cancer Ther 2008; 7: 2933-2940
7. Stewart ML, Fire E, Keating AE, Walensky LD. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 2010; 6: 595-601
8. Rangel R, Guzman-Rojas L, le Roux LG, Staquicini FI, Hosoya H, Barbu EM et al. Combinatorial targeting and discovery of ligand-receptors in organelles of mammalian cells. Nat Commun 2012; 3: 788
9. Dartois V, Sanchez-Quesada J, Cabezas E, Chi E, Dubbelde C, Dunn C et al. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob Agents Chemother 2005; 49: 3302-3310
10. Lockshin RA, Zakeri Z. Cell death in health and disease. J Cell Mol Med 2007; 11: 1214-1224
11. Jin TG, Kurakin A, Benhaga N, Abe K, Mohseni M, Sandra F et al. Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5. J Biol Chem 2004; 279: 55594-55601
12. Ozturk S, Schleich K, Lavrik IN. Cellular FLICE-like inhibitory proteins (c-FLIPs): Fine-tuners of life and death decisions. Exp Cell Res 2012; 318: 1324-1331
13. Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: Back to basics. Adv Drug Delivery Rev 2005; 57: 559-577
14. Bechinger B, Lohner K. Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochimica et biophysica acta 2006; 1758: 1529-1539
15. Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochimica et biophysica acta 2008; 1778: 357-375
16. Teixeira V, Feio MJ, Bastos M. Role of lipids in the interaction of antimicrobial peptides with membranes. Prog Lipid Res 2012; 51: 149-177
17. Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, de Jong S. Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer. Biochimica et biophysica acta 2010; 1805: 123-140
18. Day TW, Huang S, Safa AR. c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells. Biochem Pharmacol 2008; 76: 1694-1704
19. Peter ME. Programmed cell death: Apoptosis meets necrosis. Nature 2011; 471: 310-312
20. Matsuzaki K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochimica et biophysica acta 1999; 1462: 1-10
21. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochimica et biophysica acta 1999; 1462: 55-70
22. Sasisekharan R, Raman R, Prabhakar V. Glycomics approach to structure-function relationships of glycosaminoglycans. Annu Rev Biomed Engineering 2006; 8: 181-231
23. Rabenstein DL. Heparin and heparan sulfate: Structure and function. Natural Product Rep 2002; 19: 312-331
24. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Investig 1998; 102: 1662-1673
25. Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 2001; 61: 5562-5569
26. Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004; 10: 6612-6621
27. Fadnes B, Rekdal O, Uhlin-Hansen L. The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells. BMC Cancer 2009; 9: 183
28. Fadnes B, Uhlin-Hansen L, Lindin I, Rekdal O. Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells. BMC Cancer 2011; 11: 116
29. Urbinati C, Nicoli S, Giacca M, David G, Fiorentini S, Caruso A et al. HIV-1 Tat and heparan sulfate proteoglycan interaction: A novel mechanism of lymphocyte adhesion and migration across the endothelium. Blood 2009; 114: 3335-3342
30. Hsu CC, Lin TW, Chang WW, Wu CY, Lo WH, Wang PH et al. Soyasaponin-I-modified invasive behavior of cancer by changing cell surface sialic acids. Gynecol Oncol 2005; 96: 415-422
31. Ulloa F, Real FX. Differential distribution of sialic acid in alpha2,3 and alpha2,6 linkages in the apical membrane of cultured epithelial cells and tissues. J Histochem Cytochem 2001; 49: 501-510
32. Schwartz MA. Integrins, oncogenes, and anchorage independence. J Cell Biol 1997; 139: 575-578
33. Dusek RL, Attardi LD. Desmosomes: New perpetrators in tumour suppression. Nat Rev Cancer 2011; 11: 317-323
34. Del Gaizo V, MacKenzie JA, Payne RM. Targeting proteins to mitochondria using TAT. Mol Genet Metabolism 2003; 80: 170-180
35. Tait SW, Green DR. Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11: 621-632
36. Fjell CD, Hiss JA, Hancock RE, Schneider G. Designing antimicrobial peptides: Form follows function. Nat Rev Drug Discov 2012; 11: 37-51
37. Song K, Benhaga N, Anderson RL, Khosravi-Far R. Transduction of tumor necrosis factorrelated apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. Cancer Res 2006; 66: 6304-6311